DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADB274516
Title:
Evaluation of Cyclooxygenase-2 as a Novel Target for Breast Cancer Prevention
Descriptive Note:
Final rept. 1 Jul 1998-30 Jun 2001
Corporate Author:
CORNELL UNIV MEDICAL COLL (WEILL) NEW YORK
Report Date:
2001-07-01
Pagination or Media Count:
53.0
Abstract:
The inducible prostaglandin synthase cyclooxygenase-2 Cox-2 is expressed in a variety of human cancers, but its role in breast cancer has not been definitively established. Our research was designed to test whether Cox-2 is important in the pathogenesis of mammary cancer using Wnt-1 as a model mammary oncogene. Wnt-1 transgenic mice exhibit mammary hyperplasia and subsequently develop mammary carcinomas. Additionally, some mouse mammary epithelial cell lines are transformed by Wnt-1 expression. We have demonstrated upregulation of Cox-2 gene transcription in Wnt-1 expressing cell lines, and in mammary tumors from Wnt-1 transgenic mice. Our experiments suggest that Ets family transcription factors contributes to the observed Cox-2 upregulation. Firstly, we have observed that the Ets factor PEA3 is upregulated in response to Wnt-1 expression in C57MG mouse mammary epithelial cells, and PEA3 factors are highly expressed in tumors from Wnt-1 transgenic mice. Secondly, we have demonstrated that PEA3 potently activates transcription of the Cox-2 gene. In addition, we have tested the role of Cox-2 in mammary tumorigenesis by generating Wnt-1 transgenic mice of the following Cox-2 genotypes 1, 1- and -I-, and then evaluating the incidence of mammary hyperplasia and carcinoma formation in these animals. The results of these analyses are described herein.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
